Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

Eli Lilly (NYSE: LLY) is a screaming buy because it makes the most potent weight-loss drug that's on the market right now, Zepbound. Zepbound is already a blockbuster less than a year out from its ...

MSNBC and CNN Fight to Dig Out of a Postelection Ratings Hole Ratings for the No. 2 and No. 3 cable news networks have plummeted since Donald Trump's victory, while Fox News remains the leader. ABC ...

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason.

Stocks looked set to rise on Monday ahead of a busy week for central banks. A decision by the Federal Reserve will be the highlight, while other interest-rate decisions are due from Japan, the U.K., ...

Keith Speights (Eli Lilly): Five years ago, Eli Lilly was a large pharmaceutical ... and under the brand name Zepbound as a weight-loss therapy. So far in 2024, Lilly's tirzepatide franchise has raked ...

The marketing initiative touts the protein and fiber content of the offerings, which appeals to consumers taking weight-loss medications such as Ozempic and Wegovy.

Americans pay more for health care but don't get better results. Why? The blame goes well beyond insurance companies.